HABA LaboratoriesInc Full Year 2025 Earnings: EPS: JP¥152 (vs JP¥560 loss in FY 2024)

Simply Wall St

May 11, 2025

HABA LaboratoriesInc (TSE:4925) Full Year 2025 Results

Key Financial Results

Revenue: JP¥12.1b (down 2.1% from FY 2024).
Net income: JP¥576.0m (up from JP¥2.12b loss in FY 2024).
Profit margin: 4.8% (up from net loss in FY 2024). The move to profitability was driven by lower expenses.
EPS: JP¥152 (up from JP¥560 loss in FY 2024).

We've discovered 3 warning signs about HABA LaboratoriesInc. View them for free.

earnings-and-revenue-history — TSE:4925 Earnings and Revenue History May 11th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

HABA LaboratoriesInc's share price is broadly unchanged from a week ago.

Risk Analysis

We should say that we've discovered 3 warning signs for HABA LaboratoriesInc (1 doesn't sit too well with us!) that you should be aware of before investing here.

Valuation is complex, but we're here to simplify it.

Discover if HABA LaboratoriesInc might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.